Biological activities of lipopolysaccharides of Proteus spp. and their interactions with polymyxin B and an 18-kDa cationic antimicrobial protein (CAP18)-derived peptide

Journal of Medical Microbiology

Volumn 49, Issue 2, 2000, Pages 127-138

  Swierzko, Anna St ^f   Kirikae, Teruo ^a,b,f   Kirikae, Fumiko ^a,b,f   Hirata, Michimasa ^c,f   Cedzynski, Maciej ^f   Ziolkowski, Andrzej ^f   Hirai, Yosikazu ^a,f   Kusumoto, Shoichi ^d,f   Yokochi, Takashi ^e,f   Nakano, Masayasu ^a,f  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e AICHI MEDICAL UNIVERSITY   (Japan)

^f POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIGEN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; LIPID A; NITRIC OXIDE; POLYMYXIN B; TUMOR NECROSIS FACTOR;

ANAPHYLAXIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ESCHERICHIA COLI; FEMALE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEUS; PROTEUS VULGARIS; PSEUDOMONAS AERUGINOSA;

EID: 0033962622     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-49-2-127     Document Type: Article

References (63)

1. 1. Senior BW. Proteus, Morganella and Providencia. In: Collier L, Balows A, Sussman M (eds) Topley & Wilson's microbiology and microbial infections, 9th edn, vol 2: Systematic bacteriology. London, Arnold. 1998: 1035-1050.
2. 2. Rózàlski A, Sidorczyk Z, Kotelko K. Potential virulence factors of Proteus bacilli. Microbiol Mol Biol Rev 1997; 61: 65-89.
3. 3. Sidorczyk Z, Zähringer U, Rietschel ET. Chemical structure of the lipid A component of the lipopolysaccharide from a Proteus mirabilis Re-mutant, Eur J Biochem 1983; 137: 15-22.
4. 4. Vinogradov EV, Thomas-Oates JE, Brade H, Holst O. Structural investigation of the lipopolysaccharide from Proteus mirabilis R45 (Re-chemotype). J Endotoxin Res 1994; 1: 199-206.
5. 5. Knirel YA, Vinogradov EV, Shashkov AS et al. Structural study of O-specific polysaccharides of Proteus. J Carbohydr Chem 1993; 12: 379-414.
6. 6. Shimizu T, Akiyama S-I, Masuzawa T et al. Biological activities of chemically synthesized Proteus-type lipid A. Microbiol Immunol 1987; 31: 381-386.
7. 7. Galanos C, Lüderitz O, Westphal O. A new method for the extraction of R lipopolysaccharides. Eur J Biochem 1969; 9: 245-249.
8. 8. Vinogradov EV, Shashkov AS, Knirel YA et al. Structure of the O-antigen of Francisella tularensis strain 15. Carbohydr Res 1991; 214: 289-297.
9. 9. Lambden PR, Heckels JE. Synthesis of immunogenic oligosaccharide-protein conjugates from the lipopolysaccharide of Neisseria gonorrhoeae P9. J Immunol Methods 1982; 48: 233-240.
10. 10. Yokochi T, Inoue Y, Yokoo J, Kimura Y, Kato N. Retention of bacterial lipopolysaccharide at the site of subcutaneous injection. Infect Immun 1989; 57: 1786-1791.
11. 11. Imoto M, Yoshimura N, Kusumoto S, Shiba T. Total synthesis lipid A, active principle of the bacterium bacterial endotoxin. Proc Jpn Acad Ser 1984; B.60: 285-288.
12. 12. Cedzynski M, Knirel YA, Amano K-I et al. Structural and serological studies of the O-antigen of Proteus vulgaris OX2 (serogroup O2) used in the Weil-Felix test. Biochemistry (Moscow) 1997; 62: 15-20.
13. 13. Cedzyński M, Knirel YA, Rózalski A, Shashkov AS, Vinogradov EV, Kaca W. The structure and serological specificity of Proteus mirabilis O43 O antigen. Eur J Biochem 1995; 232: 558-562.
14. 14. Cedzyński M, Swierzko AS, Ziotkowski A et al. Structural and immunochemical studies of two cross-reactive Proteus mirabilis O-antigens, O6 and O23, containing betal → 3-linked 2-acetamido-2-deoxy-D-glucopyranose residues. Microbiol Immunol 1998; 42: 7-14.
15. 15. Kaca W, Kotelko K. Lipopolysaccharide phage receptor of Proteus mirabilis 1959 strain. Site of phage-mediated hydrolysis in O-specific polysaccharide. Arch Immunol Ther Exp 1983; 31: 691-700.
16. 16. Knirel YA, Kaca W, Paramonov NA et al. Structure of the O-specific polysaccharide of Proteus vulgaris O25 containing 3-O-[(R)-l-carboxyethyl]-D-glucose. Eur J Biochem 1997; 247: 951-954.
17. 17. Senchenkova SN, Shashkov AS, Toukach FV et al. Structure of the acid-labile galactosyl phosphate-containing O-antigen of Proteus vulgaris OX19 (serogroup O1) used in the Weil-Felix test. Biochemistry (Moscow) 1997; 62: 461-468.
18. 18. Shashkov AS, Senchenkova SN, Toukach FV et al. Structure of the O-specific polysaccharide of the bacterium Proteus mirabilis O10 containing L-alturonic acid, a new component of O-antigens. Biochemistry (Moscow) 1996; 61: 1100-1105.
19. 19. Shashkov AS, Toukach FV, Paramonov NA, Senchenkova SN, Kaca W, Knirel YA. Structure of a new lysine-containing O-specific polysaccharide of the bacterium Proteus mirabilis 026. Biochemistry (Moscow) 1996; 61: 15-22.
20. 20. Shashkov AS, Toukach FV, Paramonov NA et al. Structures of new acidic O-specific polysaccharides of the bacterium Proteus mirabilis serogroups O26 and O30. FEBS Lett 1996; 386: 247-251.
21. 21. Shashkov AS, Toukach FV, Senchenkova SN et al. Structure of the O-specific polysaccharide of the bacterium Proteus mirabilis O13 containing a novel component: an amide of D-galacturonic acid with N (epsilon)-(l-carboxyethyl)lysine. Biochemistry (Moscow) 1997; 62: 509-513.
22. 22. Shashkov AS, Toukach FV, Ziołkowski A et al. Structure of the O-specific polysaccharide of the bacterium Proteus mirabilis O30. Biochemistry (Moscow) 1996; 61: 575-579.
23. 23. Swierzko A, Cedzynski M, Knirel YA et al. Structural and serological studies of the O-antigen of the bacterium Proteus mirabilis OXK (serogroup O3) used in the Weil-Felix test. Biochemistry (Moscow) 1997; 62: 21-27.
24. 24. Swierzko A, Shashkov AS, Senchenkova SN et al. Structural and serological studies of the O-specific polysaccharide of the bacterium Proteus mirabilis O10, containing L-altruronic acid, a new component of O-antigens. FEBS Lett 1996; 398: 297-302.
25. 25. Ziołkowski A, Shashkov AS, Swierzko AS et al. Structures of the O-antigens of Proteus bacilli belonging to OX group (serogroups O1-O3) used in Weil-Felix test. FEBS Lett 1997; 411: 221-224.
26. 26. Kusumoto S, Tarumi Y, Ikenaka K, Shiba T. Chemical synthesis of N-acetylmuramyl peptides with partial structures of bacterial cell wall and their analogs in relation to immunoadjuvant activities. Bull Chem Soc Jpn 1976; 49: 533-539.
27. 27. Larrick JW, Hirata M, Balint RF, Lee J, Zhong J, Wright SC. Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun 1995; 63: 1291-1297.
28. 28. Hirata M, Wright SC, Larrick JW. Endotoxin-neutralizing proteins for sepsis and endotoxin shock. In: Okada K, Ogata H (eds) Shock. Amsterdam, Elsevier Science. 1996: 109-115.
29. 29. Galanos C, Freudenberg MA, Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA 1979; 76: 5939-5943.
30. 30. Takada H, Galanos C. Enhancement of endotoxin lethality and generation of anaphylactoid reactions by lipopolysaccharides in muramyl-dipeptide-treated mice. Infect Immun 1987; 55: 409-413.
31. 31. Kirikae T, Kirikae F, Oghiso Y, Nakano M. Microtubule-disrupting agents inhibit nitric oxide production in murine peritoneal macrophages stimulated with lipopolysaccharide or paclitaxel (Taxol). Infect Immun 1996; 64: 3379-3384.
32. 32. Kirikae T, Schade FU, Kirikae F, Rietschel ET, Morrison DC. Isolation of a macrophage-like cell line defective in binding of lipopolysaccharide. Influence of serum and lipopolysaccharide chain length on macrophage activation. J Immunol 1993; 151: 2742-2752.
33. 33. Kirikae F, Kirikae T, Qureshi N, Takayama K, Morrison DC, Nakano M. CD14 is not involved in Rhodobacter sphaeroides diphosphoryl lipid A inhibition of tumor necrosis factor alpha and nitric oxide induction by taxol in murine macrophages, Infect Immun 1995; 63: 486-497.
34. 34. Yamamoto S, Kubotsu K, Kida M et al. Automated homogeneous liposome-based assay system for total complement activity. Clin Chem 1995; 41: 586-590.
35. 35. Takada H, Hirai H, Fujiwara T, Koga T, Ogawa T, Hamada S. Bacteroides lipopolysaccharides (LPS) induce anaphylactoid and lethal reactions in LPS-responsive and -nonresponsive mice primed with muramyl dipeptide. J Infect Dis 1990; 162: 428-434.
36. 36. Kirikae T, Kirikae F, Saito S et al. Biological characterization of endotoxins released from antibiotic-treated Pseudomonas aeruginosa and Escherichia coli. Antimicrob Agents Chemother 1998; 42: 1015-1021.
37. 37. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249: 1431-1433.
38. 38. Kirikae T, Kirikae F, Tominaga K, Qureshi N, Yamamoto S, Nakano M. Rhodobacter sphaeroides diphosphoryl lipid A inhibits interleukin-6 production in CD14-negative murine marrow stromal ST2 cells stimulated with lipopolysaccharide or paclitaxel (taxol). J Endotoxin Res 1998; 4: 115-122.
39. 39. Yokochi T, Inoue Y, Kimura Y, Kato N. Strong interaction of lipopolysaccharides possessing the mannose homopolysaccharides with complement and its relation to adjuvant action. J Immunol 1990; 144: 3106-3110.
40. 40. Kirikae T, Hirata M, Yamasu H et al. Protective effects of a human 18-kilodalton cationic antimicrobial protein (CAP18)-derived peptide against murine endotoxemia. Infect Immun 1998; 66: 1861-1868.
41. 41. Ishikawa Y, Kirikae T, Hirata M et al. Local skin response in mice induced by a single intradermal injection of bacterial lipopolysaccharide and lipid A. Infect Immun 1991; 59: 1954-1960.
42. 42. Morrison DC, Kline LF. Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS). J Immunol 1977; 118: 362-368.
43. 43. Kirikae T, Inada K, Hirata M, Yoshida M, Galanos C, Lüderitz O. Hemagglutination induced by lipopolysaccharides and lipid A. Microbiol Immunol 1986; 30: 269-274.
44. 44. Lüderitz T, Brandenburg K, Seydel U, Roth A, Galanos C, Rietschel ET. Structural and physicochemical requirements of endotoxins for the activation of arachidonic acid metabolism in mouse peritoneal macrophages in vitro. Eur J Biochem 1989; 179: 11-16.
45. 45. Flebbe LM, Chapes SK, Morrison DC. Activation of C3H/HeJ macrophage tumoricidal activity and cytokine release by R-chemotype lipopolysaccharide preparations. Different effects of IFN-γ. J Immunol 1990; 145: 1505-1511.
46. 46. Flebbe L, Vukajlovich SW, Morrison DC. Immunostimulation of C3H/HeJ lymphoid cells by R-chemotype lipopolysaccharide preparations. J Immunol 1989; 142: 642-652.
47. 47. Suda Y. Kirikae T, Shiyama T et al. Macrophage activation in response to S-form lipopolysaccharides (LPS) separated by centrifugal partition chromatography from wild-type LPS: effects of the O-polysaccharide portion of LPS. Biochem Biophys Res Commun 1995; 210: 678-685.
48. 48. Schumann RR, Leong SR, Flaggs GW et al. Structure and function of lipopolysaccharide binding protein. Science 1990; 249: 1429-1431.
49. 49. Wright SD, Ramos RA, Patel M, Miller DS. Septin: a factor in plasma that opsonizes lipopolysaccharide-bearing particles for recognition by CD14 on phagocytes. J Exp Med 1992; 176: 719-727.
50. 50. Morrison DC, Danner RL, Dinarello CA et al. Bacterial endotoxins and pathogenesis of Gram-negative infections: current status and future direction. J Endotoxin Res 1994; 1: 71-83.
51. 51. Chen T-Y, Bright SW, Pace JL, Russell SW, Morrison DC. Induction of macrophage-mediated tumor cytotoxicity by a hamster monoclonal antibody with specificity for lipopolysaccharide receptor. J Immunol 1990; 145: 8-12.
52. 52. Cohen L, Haziot A, Shen DR et al. CD14-independent responses to LPS require a serum factor that is absent from neonates. J Immunol 1995; 155: 5337-5342.
53. 53. Lynn WA, Liu Y, Golenbock DT. Neither CD14 nor serum is absolutely necessary for activation of mononuclear phagocytes by bacterial lipopolysaccharide. Infect Immun 1993; 61: 4452-4461.
54. 54. Endo Y, Shibazaki M, Nakamura M, Takada H. Contrasting effects of lipopolysaccharides (endotoxins) from oral blackpigmented bacteria and Enterobacteriaceae on platelets, a major source of serotonin, and on histamine-forming enzyme in mice. J Infect Dis 1997; 175: 1404-1412.
55. 55. Jiang G-Z, Sugiyama T, Kato Y, Koide N, Yokochi T. Binding of mannose-binding protein to Klebsiella O3 lipopolysaccharide possessing the mannose homopolysaccharide as the O-specific polysaccharide and its relation to complement activation. Infect Immun 1995; 63: 2537-2540.
56. 56. Matsushita M. The lectin pathway of the complement system. Microbiol Immunol 1996; 40: 887-893.
57. 57. Holmskov U, Malhotra R, Sim RB, Jensenius JC. Collectins: collagenous C-type lectins of the innate immune defense system. Immunol Today 1994; 15: 67-74.
58. 58. Radziejewska-Lebrecht J, Mayer H. The core region of Proteus mirabilis R110/1959 lipopolysaccharide. Eur J Biochem 1989; 183: 573-581.
59. 59. Mayer H, Bhat UR, Masoud H, Radziejewska-Lebrecht J, Widemann C, Krauss JH. Bacterial lipopolysaccharides. Pure Appl Chem 1989; 61: 1271-1282.
60. 60. Rietschel ET, Seydel U, Zähringer U et al. Bacterial endotoxin: molecular relationships between structure and activity. Infect Dis Clin North Am 1991; 5: 753-779.
61. 61. Nummila K, Kilpeläinen I, Zähringer U, Vaara M, Helander IM. Lipopolysaccharides of polymyxin B-resistant mutants of Escherichia coli are extensively substituted by 2-aminoethyl pyrophosphate and contain aminoarabinose in lipid A. Mol Microbiol 1995; 16: 271-278.
62. 62. Boll M, Radziejewska-Lebrecht J, Warth C, Krajewska-Pietrasik D, Mayer H. 4-amino-4-deoxy-L-arabinose in LPS of enterobacterial mutants and its possible role for their polymyxin B reactivity. FEMS Immunol Med Microbiol 1994; 8: 329-341.
63. 63. Brade H, Brabetz W, Brade L et al. Chlamydial lipopolysaccharide. J Endotoxin Res 1997; 4: 67-84.